Screener
Dianthus Therapeutics DNTH Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock; $0.001 par value per share; authorized shares – 10,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding – none at March 31, 2026 and December 31, 2025 | — | — |
| Common stock; $0.001 par value per share; authorized shares – 150,000,000 at March 31, 2026 and December 31, 2025; issued and outstanding shares –54,582,749 and 43,223,090 at March 31, 2026 and December 31, 2025, respectively | 54 | 43 |
| Additional paid-in capital | 1,579,398 | 829,598 |
| Accumulated deficit | (377,563) | (336,729) |
| Accumulated other comprehensive (loss)/income | (575) | 489 |
| Total stockholders’ equity | 1,201,314 | 493,401 |
| Total liabilities and stockholders’ equity | $1,246,884 | $530,922 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's total liabilities & equity?
- Dianthus Therapeutics (DNTH) reported total liabilities & equity of $1.25B in Q1 2026.
- How has Dianthus Therapeutics's total liabilities & equity changed year-over-year?
- Dianthus Therapeutics's total liabilities & equity increased by 257.7% year-over-year, from $348.58M to $1.25B.
- What is the long-term trend for Dianthus Therapeutics's total liabilities & equity?
- Over 5 years (2020 to 2025), Dianthus Therapeutics's total liabilities & equity has grown at a 26.9% compound annual growth rate (CAGR), from $161.62M to $530.92M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Dianthus Therapeutics's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude